Dermatology
Advertisement
AI model uses smartphone images to objectively track eczema severity.
Phase 3 trial shows ivarmacitinib is effective and safe for moderate to severe atopic dermatitis in teens and adults.
Researchers identified the pathologic and clinical characteristics of patients who experience disease relapse.
Study finds early lebrikizumab response in AD linked to lower inflammation—may guide personalized treatment plans.
Treatment with the drug demonstrated lesion and pain control in moderate to severe disease.
Symptomatic benefits of treatment on the severity of pustules, erythema, and scaling were observed.
TLR9 gene variants may influence vitiligo risk, new research suggests innate immunity plays a key role.
Elevated bilirubin levels may lower vitiligo risk, suggesting a protective role, new genetic study finds.
Tofacitinib shows promising 6-month results for alopecia totalis and universalis, with notable hair regrowth and safety profi
Topical JAK inhibitors show promise for vitiligo, but current evidence lacks strong statistical support, study finds.
PEPITEM and its analogues show promise as steroid-free anti-inflammatory agents in psoriasis and immune cell regulation.
Individuals with TSW had elevated levels of a form of vitamin B3, causing inflammation separate from eczema symptoms.
Topical application of PEPITEM addressed systemic inflammation, suggesting therapeutic benefit beyond the skin.
The researchers focused on microbial changes that occur from childhood to adulthood and stability of existing microbiomes.
A new pattern of nonscarring alopecia, termed macular alopecia, may represent an underrecognized clinical entity.
The correlation between stigma and chronic skin disease negatively affects childrens' mental health according to the study.
Relative rates of serious infection were calculated using medication use time versus time not used.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.